Compare Hims and Hers Health Inc (HIMS) vs Honest Company Inc (HNST) Price & Performance

HIMS stock trades at $28.06, down 5.01% on the day, amid a bearish technical signal and negative earnings surprises. The company reported a net loss of $142 million in 2026, with a negative net income margin of -5.51%, despite revenue growth to $2.6 billion. Multiple securities class action lawsuits filed in October 2026 create significant legal overhang, while analyst consensus remains mixed with a $32.17 price target but only 35% buy ratings.

The outlook is clouded by profitability challenges and legal risks, though revenue growth offers a potential catalyst if margins improve. Investors face substantial downside risk from ongoing litigation and weak earnings, offset by analyst price targets suggesting modest upside from current levels if operational execution improves.

HNST trades at $4.97, up 0.81% with a bearish technical outlook despite recent institutional buying. The company shows mixed fundamentals with Q2 2026 earnings beating estimates but negative profit margins and declining revenue guidance for 2026. Analyst consensus is cautious with a $5.30 price target and 30% buy rating distribution.

The stock faces headwinds from negative profitability and competitive pressures, though strategic exits show early turnaround signs. Upside potential exists if margin improvements continue, but investors should weigh execution risks against institutional accumulation trends.